Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 9, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review

Soo Han Kim1,2,3, Hayoung Seong1,2, Hyojin Jang1,2

  • 1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.

Thoracic Cancer
|July 7, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary Healthcare Utilization of Undocumented Migrants in Busan, South Korea: A Retrospective Chart Review of a Free Clinic From 2020 to 2024.

Journal of preventive medicine and public health = Yebang Uihakhoe chi·2026
Same author

Cohort profile: a multicenter hospital-based cohort of tuberculosis and nontuberculous mycobacterial pulmonary disease in Korea, 2015-2024.

Epidemiology and health·2026
Same author

AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3-4 Pulmonary Nodules: A Multicenter Prospective Cohort Study.

Biomedicines·2026
Same author

Clinical outcomes of heart failure with improved ejection fraction in patients treated with angiotensin receptor-neprilysin inhibitor.

The Korean journal of internal medicine·2026
Same author

Outcomes in patients with multidrug- or rifampin-resistant tuberculosis treated with bedaquiline and/or delamanid under the South Korean nationwide approval process.

BMC infectious diseases·2026
Same author

Impact of vitamin D deficiency on 6-month culture conversion in nontuberculous mycobacterial pulmonary disease.

Scientific reports·2026

EGFR mutation status does not impact recurrence or disease-free survival in resected non-small cell lung cancer (NSCLC). However, adjuvant EGFR-tyrosine kinase inhibitors (TKIs) significantly improve survival, supporting their use post-surgery.

Area of Science:

  • Oncology
  • Pulmonology
  • Molecular Biology

Background:

  • The prognostic role of Epidermal Growth Factor Receptor (EGFR) mutations in resected non-small cell lung cancer (NSCLC) is unclear.
  • EGFR mutations are known predictors in advanced NSCLC but their impact on early-stage disease recurrence is uncertain.

Purpose of the Study:

  • To evaluate the prognostic significance of EGFR mutation status on recurrence and disease-free survival (DFS) in patients with resected stage I-III NSCLC.
  • To analyze recurrence patterns and the efficacy of adjuvant therapies based on EGFR status.

Main Methods:

  • Systematic review and meta-analysis of studies on resected stage I-III NSCLC.
  • Searched PubMed, Embase, and Cochrane Library for studies reporting recurrence or DFS by EGFR status.
Keywords:
EGFR mutationdisease‐free survivalmeta‐analysisnon‐small cell lung cancerprognosisrecurrence

Related Experiment Videos

Last Updated: Jul 9, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

  • Calculated pooled recurrence rates, risk ratios (RR), and hazard ratios (HR) using random-effects models.

    • Main Results:

    • Analysis of 20 studies (12,123 patients) showed no significant difference in recurrence (RR 1.04) or DFS (HR 1.07) between EGFR-mutant and wild-type NSCLC.
    • Recurrence patterns, including local, distant, and central nervous system relapse, were comparable.
    • Adjuvant EGFR-tyrosine kinase inhibitors (TKIs) significantly improved DFS in EGFR-mutant NSCLC (HR 0.45), whereas chemotherapy did not (HR 1.05).

    Conclusions:

    • EGFR mutation status is not a prognostic factor for recurrence or DFS in resected NSCLC.
    • Adjuvant EGFR-TKIs demonstrate significant DFS benefit in EGFR-mutant NSCLC, suggesting their role in postoperative treatment.
    • Chemotherapy does not appear to provide a DFS benefit in this context.